Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types

Pharmacological Research(2024)10.1016/j.phrs.2024.107092Source: DataRank Database

New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types is a research paper published in Pharmacological Research (2024). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 7.73)OA: goldTopics (40)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

Hye‐ran Moon ORCID,Randall Wireman,Jacqueline Peil,Sonia Kiran ORCID,Dana K. Mitchell ORCID

Live enrichment

PubMed:38311014 OpenAlex:https://openalex.org/W4391486812

NCI NIH HHS

Grant: R01 CA205166

NCI NIH HHS

Grant: R01 CA282478

NHLBI NIH HHS

Grant: U01 HL143403

NCI NIH HHS

Grant: R01 CA264471

NCATS NIH HHS

Grant: UL1 TR002529

NCI NIH HHS

Grant: U01 CA274304

NCI NIH HHS

Grant: R01 CA231267

NCI NIH HHS

Grant: P30 CA082709

NCI NIH HHS

Grant: R01 CA254110

NHLBI NIH HHS

Grant: R01 HL140961

NEI NIH HHS

Grant: R01 EY031939

NCI NIH HHS

Grant: R01 CA167291

FWCI

7.73

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.phrs.2024.107092

publisherhttps://doi.org/10.1016/j.phrs.2024.107092

publisherhttps://api.elsevier.com/content/article/PII:S1043661824000367?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1043661824000367?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38311014

Fields of Study

Chronic Lymphocytic Leukemia ResearchBiochemical and Molecular ResearchAdenosine and Purinergic SignalingAdultHumansAnimalsMiceDNA-(Apurinic or Apyrimidinic Site) LyaseAngiogenesis InhibitorsApoptosisBiological AssayNeoplasmsTumor Microenvironment

MeSH Terms

AdultAnimalsBiological AssayHumansNeoplasmsApoptosisAngiogenesis InhibitorsDNA-(Apurinic or Apyrimidinic Site) LyaseMiceTumor Microenvironment

Keywords

PotencyCancerComputational biologyMedicineCancer researchPharmacologyBiologyInternal medicineGeneticsIn vitroCancersHypoxia Inducible Factor 1 (HIF1α)MPNSTNovel targeted inhibitorsNuclear Factor kappa B (NFκB)PDACRef-1 redox function

Sustainable Development Goals

SDG 0: Good health and well-being